Skip to content

An evaluation to compare Bisept mouthwash with chlorhexidine 0.2% mouthwash based on the influence on gingival inflammation and dental staining

A clinical trial to compare the effect of Bisept mouthwash with Chlorhexidine 0.2% mouthwash on gingival inflammation and dental staning in gingivitis and mild periodontitis patients

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT2016031527056N1
Enrollment
30
Registered
2017-06-11
Start date
2016-12-21
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Condition 1: Mild Chronic Periodontitis. Condition 2: Gingivitis. Chronic Periodontitis Chronic Gingivitis

Interventions

Intervention 1: Intervention in control group includes 15ml chlorhexidine 0.2% (standard) mouth wash twice daily for 4 weeks. Intervention 2: Intervention in test group includes a15ml Bisept mouth was
Treatment - Drugs
Intervention in control group includes 15ml chlorhexidine 0.2% (standard) mouth wash twice daily for 4 weeks
Intervention in test group includes a15ml Bisept mouth wash twice daily for 4 weeks

Sponsors

Vice Chancellor for Research and Technology, Kerman University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 50 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria are: Age 18_50 years old; The presence of plaque induced gingivitis (Gingival Index = 2) or mild periodontitis (1_2 mm Clinical Attachment Loss) so that redness and edema of gingiva and bleeding on probing to be seen on clinical examination; At least 20 teeth present in the mouth (teeth with improper or extensive restorations, extensive caries and third molars would be excluded); Systemically healthy patients. Exclusion criteria are: A condition that affects immune system such as diabetes and pregnancy; The habit of smoking, alcohol or tobacco consumption; Antibiotics, anti-inflammatory and immunosuppressive drugs intake or mouthwash consumption during the last three months; The presence of removable or fixed appliances in the mouth; Periodontal treatment during the last three months.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Tooth Staining. Timepoint: Baseline, 2 weeks, 4 weeks. Method of measurement: Lobene stain index.;Gingival inflammation. Timepoint: Baseline, 2 weeks, 4 weeks. Method of measurement: Modified Gingival Index.;Gingival inflammation. Timepoint: Baseline, 2 weeks, 4 weeks. Method of measurement: Bleeding Index using periodontal probe.

Secondary

MeasureTime frame
Dental plaque accumulation. Timepoint: Baseline, 2 weeks, 4 weeks. Method of measurement: Oleary plaque Index.;Dental plaque accumulation. Timepoint: 4 weeks. Method of measurement: Observation _ Turesky plaque index.;Side effects or discomfort. Timepoint: 4 weeks. Method of measurement: question.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactNazila Lashkarizadeh

Kerman dental school

n_lashkari@kmu.ac.ir, nazilalashkarizadeh@yahoo.com+98 34 3211 8071

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026